These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 25083132)

  • 41. Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes.
    Friedrich C; Emser A; Woerle HJ; Graefe-Mody U
    Am J Ther; 2013; 20(6):618-21. PubMed ID: 23411609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.
    Nakamura Y; Tsuji M; Hasegawa H; Kimura K; Fujita K; Inoue M; Shimizu T; Gotoh H; Goto Y; Inagaki M; Oguchi K
    Hemodial Int; 2014 Apr; 18(2):433-42. PubMed ID: 24405885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diabetic nephropathy: new approaches for improving glycemic control and reducing risk.
    Schernthaner G; Schernthaner GH
    J Nephrol; 2013; 26(6):975-85. PubMed ID: 23807645
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.
    Schernthaner G; Barnett AH; Emser A; Patel S; Troost J; Woerle HJ; von Eynatten M
    Diabetes Obes Metab; 2012 May; 14(5):470-8. PubMed ID: 22268497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Sep; 68(9):479-85. PubMed ID: 24180204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies.
    Lehrke M; Marx N; Patel S; Seck T; Crowe S; Cheng K; von Eynatten M; Johansen OE
    Clin Ther; 2014 Aug; 36(8):1130-46. PubMed ID: 25015594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Sesti G; Avogaro A; Belcastro S; Bonora BM; Croci M; Daniele G; Dauriz M; Dotta F; Formichi C; Frontoni S; Invitti C; Orsi E; Picconi F; Resi V; Bonora E; Purrello F
    Acta Diabetol; 2019 Jun; 56(6):605-617. PubMed ID: 30603867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR
    Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial.
    Guthrie R
    Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linagliptin for elderly patients with type 2 diabetes.
    Salvo F; Moore N; Pariente A
    Lancet; 2014 Jan; 383(9914):307. PubMed ID: 24461122
    [No Abstract]   [Full Text] [Related]  

  • 54. Linagliptin for elderly patients with type 2 diabetes.
    Shah R
    Lancet; 2014 Jan; 383(9914):306-7. PubMed ID: 24461121
    [No Abstract]   [Full Text] [Related]  

  • 55. Linagliptin for elderly patients with type 2 diabetes.
    Yamada T
    Lancet; 2014 Jan; 383(9914):306. PubMed ID: 24461120
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.
    Chen L; Klein T; Leung PS
    Curr Mol Med; 2012 Sep; 12(8):995-1004. PubMed ID: 22804249
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Linagliptin for elderly patients with type 2 diabetes - Authors' reply.
    Barnett AH; von Eynatten M; Patel S; Woerle HJ
    Lancet; 2014 Jan; 383(9914):307-8. PubMed ID: 24461123
    [No Abstract]   [Full Text] [Related]  

  • 60. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.